Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.
暂无分享,去创建一个
[1] A. Morris,et al. Misinterpretation of Surgeons' Statements on Cancer Removal-The Adverse Effects of "We Got It All". , 2022, JAMA oncology.
[2] Amie C O'Donoghue,et al. Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion. , 2021, The oncologist.
[3] A. Duits,et al. An urgent call to raise the bar in oncology , 2021, British Journal of Cancer.
[4] A. McGuire,et al. Direct-to-Consumer Drug Advertisement and Prescribing Practices: Evidence Review and Practical Guidance for Clinicians , 2020, Journal of General Internal Medicine.
[5] Amie C O'Donoghue,et al. Patients' Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups. , 2020, The oncologist.
[6] M. Vassar,et al. Evaluation of Selective Outcome Reporting Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology Drugs , 2020, Journal of General Internal Medicine.
[7] E. Hyams,et al. Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer , 2020, Prostate Cancer and Prostatic Diseases.
[8] Brian G. Southwell,et al. Patients' understanding of oncology clinical endpoints: A literature review. , 2020, Patient education and counseling.
[9] G. Sledge,et al. Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology , 2020, Cancer.
[10] J. Berktold,et al. Consumer understanding of the scope of FDA's prescription drug regulatory oversight: A nationally representative survey , 2019, Pharmacoepidemiology and drug safety.
[11] E. Eisenhauer,et al. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. , 2019, JAMA oncology.
[12] L. Amiri-Kordestani,et al. Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer , 2019, The oncologist.
[13] Vanessa Boudewyns,et al. Consumer Reactions to Price Comparison and Disclosure Information in Prescription Drug Print Advertising , 2018, Journal of Consumer Affairs.
[14] L. Howie,et al. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review , 2018, JAMA oncology.
[15] L. Squiers,et al. Quantitative Information on Oncology Prescription Drug Websites , 2018, Journal of Cancer Education.
[16] Vanessa Boudewyns,et al. Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements , 2017, Research in social & administrative pharmacy : RSAP.
[17] S. Emery,et al. Effect of Direct-to-Consumer Advertising on Statin Use in the United States , 2017, Medical care.
[18] Vanessa Boudewyns,et al. Physician response to contextualized price-comparison claims in prescription drug advertising* , 2017, Journal of communication in healthcare.
[19] J. B. Layton,et al. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013 , 2017, JAMA.
[20] G. Abel,et al. Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. , 2016, JAMA oncology.
[21] Sherry Emery,et al. Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009. , 2015, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[22] R. Rasu,et al. Health Literacy Impact on National Healthcare Utilization and Expenditure , 2015, International journal of health policy and management.
[23] Kay Miller,et al. Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use. , 2015, American journal of respiratory and critical care medicine.
[24] Sumit R. Majumdar,et al. The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis , 2015, Journal of General Internal Medicine.
[25] E. Saad,et al. Treatment priorities in oncology: do we want to live longer or better? , 2014, Clinics.
[26] J. Niederdeppe,et al. Direct-To-Consumer Television Advertising Exposure, Diagnosis with High Cholesterol, and Statin Use , 2013, Journal of General Internal Medicine.
[27] D. Schrag,et al. Impact of oncology‐related direct‐to‐consumer advertising , 2013, Cancer.
[28] G. Abel,et al. Update on Direct-to-Consumer Marketing in Oncology. , 2012, Journal of oncology practice.
[29] Lisa M. Schwartz,et al. Communicating uncertainties about prescription drugs to the public: a national randomized trial. , 2011, Archives of internal medicine.
[30] K. Viswanath,et al. Cancer-related direct-to-consumer advertising: a critical review , 2011, Nature Reviews Cancer.
[31] G. Abel,et al. Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Siamak Noorbaloochi,et al. Validation of Screening Questions for Limited Health Literacy in a Large VA Outpatient Population , 2008, Journal of General Internal Medicine.
[33] Barry D. Weiss,et al. Brief Report: screening items to identify patients with limited health literacy skills , 2006, Journal of General Internal Medicine.
[34] Thomas J. Smith,et al. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M S Wilkes,et al. Direct-to-consumer prescription drug advertising: trends, impact, and implications. , 2000, Health affairs.
[36] L. Fallowfield,et al. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits , 2016, Supportive Care in Cancer.